

Peter Verhamme

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11367232/peter-verhamme-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

16,080
citations

36
h-index

82
g-index

82
ext. papers

19,330
ext. citations

15.1
avg, IF

5.92
L-index

#	Paper	IF	Citations
77	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2010 , 363, 2499-510	59.2	2240
76	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1287-97	59.2	1692
75	Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 369, 1406-15	59.2	1298
74	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015 , 373, 511-20	59.2	1223
73	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-9 ⁵ 1393	9.5	1094
72	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018 , 378, 615-624	59.2	806
71	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
70	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017 , 377, 431-441	59.2	639
69	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013 , 15, 625-51	3.9	622
68	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016 , 375, 1131-41	59.2	580
67	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019 , 380, 1326-1335	59.2	431
66	Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , 2011 , 378, 41-8	40	415
65	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
64	Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 21, 844-8	9.4	408
63	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017 , 376, 1211-1222	59.2	397
62	Factor XI antisense oligonucleotide for prevention of venous thrombosis. <i>New England Journal of Medicine</i> , 2015 , 372, 232-40	59.2	358
61	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013 , 34, 2094-106	9.5	281

60	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
59	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020 , 4, 4693-4738	7.8	187
58	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2306-2315	15.1	173
57	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017 , 38, 2137-2149	9.5	162
56	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019 , 179, 1469-1478	11.5	156
55	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018 , 20, 1231-1242	3.9	148
54	Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. <i>Circulation</i> , 2003 , 107, 1640-6	16.7	142
53	Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, 1444-8	9.4	128
52	Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. <i>Circulation</i> , 2004 , 110, 3259-69	16.7	109
51	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1439-1449	7	98
50	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 1268-76	7	71
49	Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. <i>Thrombosis Research</i> , 2015 , 136, 749-53	8.2	63
48	Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. <i>Thrombosis Journal</i> , 2014 , 12, 21	5.6	49
47	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018 , 2, 788-796	7.8	46
46	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2204-2215	15.1	45
45	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 733-8	7	42
44	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016 , 3, e228-36	14.6	41
43	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 645-50 ⁷	40	

42	Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1003-1010	7	36
41	Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions: a prospective case-control study. <i>Clinical Oral Investigations</i> , 2017, 21, 2183-2188	4.2	35
40	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-6	2.9	29
39	Monitoring and reversal strategies for new oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 95-103	2.5	29
38	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-45	14.6	23
37	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 609-617	59.2	23
36	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459	16.7	22
35	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-53	7	21
34	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14	8.2	18
33	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 1051-1058	3.7	18
32	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140	7	17
31	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307	3.9	17
30	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55,	13.6	16
29	Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 121-3	5.1	15
28	Dabigatran-associated spontaneous acute cervical epidural hematoma. <i>World Neurosurgery</i> , 2015, 83, 257-8	2.1	14
27	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021, 6, 21-29	16.2	12
26	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129	8.2	10
25	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37	8.2	10

24	Rivaroxaban for the treatment of pulmonary embolism. <i>Advances in Therapy</i> , 2013 , 30, 589-606	4.1	9
23	Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 645-58	4	9
22	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 1091-8	7	9
21	Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. <i>European Journal of Heart Failure</i> , 2019 , 21, 129-131	12.3	9
20	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. <i>Lancet, The</i> , 2022 , 399, 1383-1390	40	9
19	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2406-2414	7	7
18	Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. <i>European Cardiology Review</i> , 2021 , 16, e23	3.9	6
17	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 431-497	5.1	5
16	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021 , 52, 2096-2105	6.7	5
15	Reversal of dabigatran by idarucizumab: when and how?. <i>Expert Review of Hematology</i> , 2016 , 9, 519-28	2.8	5
14	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1097-1106	7	5
13	Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 296-300	5.1	4
12	AuthorsResponse: from monitoring to vigilance about patient adherence to new oral anticoagulants. <i>Europace</i> , 2014 , 16, 149-50	3.9	3
11	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
10	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018 , 2, e1-e7	2.7	2
9	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3008-3017	15.4	2
8	Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. <i>Journal of Market Access & Health Policy</i> , 2018 , 6, 1495974	3.7	1
7	Answer by the authors to the letter of Dr. Wang and colleagues, concerning our case report entitled "Idarucizumab for dabigatran overdose". <i>Clinical Toxicology</i> , 2017 , 55, 66	2.9	1

6	Author reply: To PMID 23625942. <i>Europace</i> , 2014 , 16, 151-2	3.9	1
5	Organizing patient-centred anticoagulant therapy. <i>Acta Cardiologica</i> , 2013 , 68, 413-5	0.9	1
4	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020 , 4, e446-e456	2.7	1
3	Tranexamic acid and bleeding in patients treated with non-vitamin K oral anticoagulants undergoing dental extraction: The EXTRACT-NOAC randomized clinical trial. <i>PLoS Medicine</i> , 2021 , 18, e1003601	11.6	1
2	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103125	7	1
1	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12566	5.1	0